Comments
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for Voriconazole tablets, used to treat fungal infections.
“Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the US Food & Drug Administration (USFDA) for Voriconazole tablets, the therapeutic equivalent to Vfend tablets,” Glenmark said in a BSE filing.
The approval has been granted for tablets in 50 mg and 200 mg strengths.
Citing IMS Health sales data, Glenmark said, for the 12 months to July 2015, the Vfend market achieved annual sales of around $91.4 million.
The company’s current portfolio consists of 102 products authorised for distribution in the US marketplace and 63 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading at Rs 1,019.40 apiece in morning trade on the BSE, down 4.44 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.